OncologyEducation presents MedOncNow
In this episode, Dr. Aalok Kumar takes us through the practical aspects of choosing between the available adjuvant intensification options in "High Risk" HR+, HER2 - Early Breast Cancer. This is timely given there is public funding for Abemaciclib and PSP support for Ribociclib.
21 episoder
Kommentarer
0Vær den første til at kommentere
Tilmeld dig nu og bliv en del af OncologyEducation presents MedOncNow-fællesskabet!